Welcome to our dedicated page for AstraZeneca SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AstraZeneca PLC (AZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. AstraZeneca files under Form 20-F for its annual report and uses Form 6-K to furnish current reports on material developments. These filings cover a broad range of topics, including clinical trial data, regulatory approvals, manufacturing investments, insider share transactions and changes in major shareholdings.
For investors following AstraZeneca’s oncology franchise, 6-K exhibits often reproduce detailed press releases on medicines such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan) and Imfinzi (durvalumab). These documents describe Phase 3 trial designs and endpoints, Breakthrough Therapy Designations, new indications in breast, lung, gastric, endometrial and ovarian cancers, and approvals in key markets. They can help readers understand how specific trials, such as DESTINY-Breast, TROPION, MATTERHORN and others, relate to AstraZeneca’s pipeline and commercial portfolio.
Filings also address Rare Diseases and Respiratory & Immunology, including updates on Koselugo (selumetinib) for neurofibromatosis type 1 and Saphnelo (anifrolumab) for systemic lupus erythematosus. Additional 6-Ks report on large capital projects, such as multi‑billion‑dollar manufacturing investments in Maryland and other US states, and on governance matters like director and senior executive share dealings or notifications of major institutional holdings.
On Stock Titan, these AZN filings are supplemented with AI-powered summaries that explain the key points of each document in plain language. Users can quickly see which filings relate to new indications, safety information, insider transactions (similar to Form 4-style disclosures for US issuers) or strategic investments. Real-time updates from EDGAR ensure that new AstraZeneca 6-Ks and other SEC submissions appear promptly, while AI insights help readers navigate lengthy technical exhibits such as clinical trial descriptions and multi-indication product updates.
AstraZeneca reported positive Phase III results from the EMERALD-3 trial in earlier-stage, unresectable hepatocellular carcinoma eligible for embolisation. The regimen combining Imfinzi (durvalumab), Imjudo (tremelimumab), lenvatinib and transarterial chemoembolisation (TACE) achieved a statistically significant and clinically meaningful improvement in progression-free survival versus TACE alone.
At an interim analysis, the combination also showed a trend toward improved overall survival, and a STRIDE regimen plus TACE arm showed strong trends for both progression-free and overall survival, although not yet formally tested. Safety was consistent with known profiles, and the trial will continue to follow overall survival and other secondary endpoints while data are shared with global regulators.
AstraZeneca PLC reported updated share capital and voting rights information. As at 31 March 2026, the company had 1,550,980,823 ordinary shares of US$0.25 in issue, all with voting rights and none held in treasury, so total voting rights equal this amount.
The company also confirmed the admission to trading on the London Stock Exchange of 491 additional ordinary shares issued under its employee share schemes between 20 and 31 March 2026, under an existing block admission dated 29 January 2021. These new shares are fully fungible with existing ordinary shares.
AstraZeneca, through its Alexion rare disease unit, reported positive global Phase III results for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy for hypophosphatasia (HPP).
In children who had never received Strensiq, the MULBERRY trial met its primary endpoint, showing statistically significant and clinically meaningful bone health improvements on the Radiographic Global Impression of Change score at week 25, with supportive gains in rickets severity and physical function measures. The CHESTNUT switch study in paediatric patients previously treated with Strensiq showed efzimfotase alfa was well-tolerated and maintained bone benefits while offering less frequent dosing.
In adolescents and adults, the HICKORY trial did not achieve statistical significance on the primary Six-Minute Walk Test endpoint versus placebo, largely due to better-than-expected placebo performance in adult-onset HPP, but showed nominally significant benefits in fatigue and in prespecified subgroups with paediatric-onset HPP across mobility, function and pain. Across all three studies, efzimfotase alfa demonstrated an acceptable safety profile, and AstraZeneca plans to present the data at a medical meeting and share them with global regulators.
AstraZeneca reported that its investigational biologic tozorakimab met the primary endpoint in both Phase III OBERON and TITANIA trials in patients with COPD. The drug significantly reduced the annualised rate of moderate-to-severe COPD exacerbations versus placebo in former smokers and in the overall population, on top of inhaled standard of care.
Tozorakimab is a potential first-in-class monoclonal antibody targeting IL‑33, uniquely blocking both reduced and oxidised forms to address inflammation and mucus dysfunction. It was generally well tolerated with a favourable safety profile. Additional Phase III COPD trials, PROSPERO and MIRANDA, are ongoing with results expected in H1 2026.
AstraZeneca PLC has admitted 45,750 new ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market. These shares were issued between 20 January 2026 and 19 March 2026 under the company’s existing block admission.
The new shares arise from AstraZeneca’s employee share schemes, meaning they were created to satisfy staff share awards or options. Following this admission, the total number of AstraZeneca ordinary shares in issue is 1,550,980,332, all fully fungible with the existing stock.
ASTRAZENECA PLC officer Mani Sharma filed an initial insider ownership report, listing current equity and award holdings in the company. Sharma directly holds 31,153.4659 ordinary shares, plus equity awards that may convert into additional shares over time.
The filing shows 2,996.3080 restricted stock units, each representing a right to receive one ordinary share that vests on November 16, 2028, with shares to be delivered on November 17, 2028. There are also 31.2970 dividend equivalent rights, which accrue on these RSUs and convert into ordinary shares on the same vesting date.
In addition, Sharma holds an employee stock option covering 195 ordinary shares at an exercise price of $123.9800 per share, exercisable from December 1, 2028 until June 1, 2029. The exercise price is originally denominated at GBP93.64, with the reported dollar value based on a stated exchange rate.
AstraZeneca PLC reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been approved in the EU as the first perioperative immunotherapy for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen is given before and after surgery, then continued as Imfinzi alone.
The approval is based on the Phase III MATTERHORN trial, where Imfinzi plus FLOT cut the risk of disease progression, recurrence or death by 29% (event-free survival HR 0.71; p<0.001) versus chemotherapy alone, with higher one- and two-year event-free rates. Final overall survival data showed a 22% reduction in the risk of death (HR 0.78; p=0.021), with an estimated 69% of patients alive at three years compared with 62% on chemotherapy alone. The safety profile and surgery completion rates were similar between arms.
AstraZeneca PLC has published its Notice of Annual General Meeting 2026 and shareholders’ circular and is dispatching them to shareholders. The digitally-enabled AGM will be held on 9 April 2026 at 14:30 (BST).
Shareholders will vote on receiving the 2025 accounts, confirming 2025 interim dividends, appointing KPMG LLP as auditor, re-electing directors, approving the remuneration report, renewing authority for the 2020 Performance Share Plan French appendix, authorising political donations, allotting shares, disapplying pre-emption rights, authorising share buybacks, and reducing the notice period for general meetings. The Notice and related documents are available on AstraZeneca’s website and via the UK National Storage Mechanism.
AstraZeneca PLC reported that Chief Executive Officer Pascal Soriot received ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan (AZPSP).
The AZPSP award, granted on 5 March 2021 with a three-year performance period and subsequent two-year holding period, vested on its fifth anniversary. Application of the original performance conditions led to 88% of the award vesting and the remainder lapsing. After dividend reinvestment and withholding of shares to cover tax obligations, Soriot acquired 101,495 ordinary shares on 5 March 2026 for nil consideration. For tax purposes, the fair market value at vest was 15,088 pence per share, based on the closing price on the previous trading day.